VEGFA and neoplasm: We have recently reported the effects of imatinib on NSCLC xenografts, showing that 4 days of therapy (50 mg kg−1 gavage) significantly decreases IFP and microvascular density, lowers VEGF levels, and improves tumour oxygen delivery (Vlahovic et al, 2006).